NGL Fine-Chem Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: NGLFINE BSE: 524774

₹2988.30

Oct. 5, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #80 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	427,010	143.5	13.7%	7.6%	—	72	8	30
Divi's Laboratories Limited	244,125	83.0	15.3%	57.8%	0.33%	70	4	51
Torrent Pharmaceuticals Limited	161,506	77.7	12.2%	35.3%	0.80%	56	0	31
Zydus Lifesciences Limited	113,616	32.6	17.3%	14.5%	0.09%	74	24	84
Cipla Limited	107,888	35.1	11.2%	-11.7%	0.97%	73	29	62
Laurus Labs Limited	106,505	122.0	17.1%	128.4%	—	78	24	53
Mankind Pharma Limited	102,382	46.9	11.7%	0.9%	—	68	12	86
Dr. Reddy's Laboratories Limited	100,411	150.9	10.9%	-3.7%	—	62	33	71
NGL Fine-Chem Limited (this stock)	1,846	36.6	14.6%	101.7%	0.06%	77	37	68

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹1,953 Cr

EV / EBITDA

22.2x

EV / Sales

3.72x

Market cap / Sales

3.52x

Earnings yield

2.73%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 144 Cr, up 34.1% YoY.

↑ Positive

Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 16 Cr, up 115.2% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	137	22	16	₹26.6300
March 31, 2026	145	15	11	₹18.3800
Dec. 31, 2025	126	19	15	₹23.8500
Sept. 30, 2025	117	11	8	₹12.7800
June 30, 2025	101	10	8	₹12.3700
March 31, 2025	93	-0	-1	₹-0.8400
Dec. 31, 2024	87	1	1	₹1.2700
Sept. 30, 2024	91	13	10	₹16.2600
June 30, 2024	88	10	8	₹12.6700
March 31, 2024	96	14	11	₹17.5600
Dec. 31, 2023	85	13	9	₹14.4000
Sept. 30, 2023	79	15	11	₹17.7600
June 30, 2023	69	9	8	₹12.6300

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	144	147	131	119	107	92	87	97	94	100	89	83	73
Operating revenue	137	145	126	117	101	93	87	91	88	96	85	79	69
Other income	7	3	5	2	7	-1	0	5	6	4	4	4	4
Operating expenses	117	127	106	103	93	89	83	81	82	83	74	66	62
Operating profit	20	18	20	14	8	4	4	11	6	13	11	13	8
Operating profit margin	14.5%	12.2%	15.9%	11.7%	7.7%	4.2%	4.1%	11.6%	7.2%	13.2%	12.9%	16.5%	11.0%
Depreciation	4	4	4	4	3	3	2	2	2	2	2	2	2
Interest	1	1	1	1	1	1	1	0	0	0	0	0	0
Exceptional items, gain / (loss)	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit before tax	22	15	19	11	10	-0	1	13	10	14	13	15	9
Tax	5	4	5	3	2	0	0	3	2	3	4	4	1
Net profit	16	11	15	8	8	—	1	10	8	11	9	11	8
EPS	26.63	18.38	23.85	12.78	12.37	-0.84	1.27	16.26	12.67	17.56	14.40	17.76	12.63
Net profit (TTM)	50	42	—	—	—	—	30	38	39	39	36	33	27
EPS (TTM)	81.64	67.38	48.16	25.58	29.06	29.36	47.76	60.89	62.39	62.35	58.60	54.06	44.33

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	489	55	42
March 31, 2025	359	24	18
March 31, 2024	329	51	39
March 31, 2023	275	27	20

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	20.5%	13.6%	505^†	370^†	345^†	288^†	330^†	266^†	158^†	118^†	101^†
Operating revenue	21.1%	13.9%	489	359	329	275	314^†	255^†	152^†	113^†	100^†
Other income	—	—	16^†	11^†	16^†	13^†	16^†	11^†	6^†	5^†	1^†
Operating expenses	—	—	430^†	335^†	285^†	248^†	252^†	181^†	122^†	94^†	74^†
Operating profit	30.3%	-4.4%	59^†	24^†	44^†	27^†	62^†	74^†	30^†	19^†	26^†
Operating profit margin	—	—	12.1%^†	6.8%^†	13.5%^†	9.7%^†	19.7%^†	29.0%^†	19.8%^†	16.8%^†	25.8%^†
Depreciation	—	—	16^†	9^†	8^†	8^†	8^†	7^†	6^†	5^†	3^†
Interest	—	—	4^†	2^†	1^†	1^†	2^†	2^†	2^†	2^†	1^†
Exceptional items, gain / (loss)	—	—	0^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†
Profit before tax	27.1%	-6.4%	55	24	51	27	69^†	76^†	28^†	18^†	22^†
Tax	—	—	13^†	6^†	12^†	6^†	17^†	21^†	7^†	5^†	—
Net profit	27.4%	-5.6%	42	18	39	20	52^†	55^†	20^†	12^†	14^†
EPS	27.5%	-5.6%	67.38^†	29.36^†	62.35^†	32.53^†	84.57^†	89.82^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 19	Mar 18	Mar 17
Operating margin	12.1%^†	6.8%^†	13.5%^†	9.7%^†	19.7%^†	29.0%^†	19.8%^†	16.8%^†	25.8%^†
EBIT margin	12.1%^†	7.3%^†	15.8%^†	10.1%^†	22.5%^†	30.5%^†	19.7%^†	16.8%^†	22.7%^†
PBT margin	11.2%	6.6%	15.4%	9.7%	22.0%^†	29.8%^†	18.2%^†	15.5%^†	22.0%^†
Net margin	8.5%	5.0%	11.7%	7.3%	16.6%^†	21.7%^†	13.3%^†	10.9%^†	14.2%^†
Interest coverage	13.38x^†	11.35x^†	38.90x^†	23.21x^†	45.17x^†	42.30x^†	13.05x^†	12.28x^†	31.51x^†
Dividend payout	2.6%^†	6.0%^†	2.8%^†	0.0%^†	0.0%^†	0.0%^†	—	—	—
Earnings retention	97.4%^†	94.0%^†	97.2%^†	100.0%^†	100.0%^†	100.0%^†	—	—	—
Current ratio	1.84x	2.01x	—	—	—	—	—	—	—
Quick ratio	1.37x	1.58x	—	—	—	—	—	—	—
Debt to equity	0.34x	0.26x	—	—	—	—	—	—	—
Return on equity	13.0%	6.5%	—	—	—	—	—	—	—
Return on assets	7.9%	4.3%	—	—	—	—	—	—	—
Return on capital employed	15.3%^†	8.4%^†	—	—	—	—	—	—	—
Asset turnover	0.92x	0.84x	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	35	-65	30	89	-54
March 31, 2025	17	-16	-1	74	-57
March 31, 2024	11	-17	-1	28	-17
March 31, 2023	32	-24	-1	29	3

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	530	320	317	51	56	265	144	1	144	68
March 31, 2025	426	280	277	47	25	230	115	1	119	49
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.